Halozyme Announces Appointment of Jim Daly to its Board of Directors
PR Newswire•30/09/2026•16:05 ET
0
Key Highlights
- ➤James “Jim” Daly appointed to Halozyme’s (HALO) Board of Directors
- ➤Jim Daly brings more than three decades of biopharmaceutical commercial leadership experience
- ➤Daly previously served on Halozyme’s (HALO) Board of Directors
- ➤ENHANZE has reached more than one million patient lives through ten commercialized products
Expert Statements
Helen Torley, President and Chief Executive Officer of Halozyme
“We are delighted to welcome Jim back to Halozyme's Board of Directors. Jim brings exceptional industry knowledge, commercial expertise, strategic insight, and governance experience. His extensive background leading the launches and growth of multiple blockbuster therapies will be invaluable as Halozyme continues to expand the number of products using our subcutaneous (SC) delivery technologies, ENHANZE, and our two hyperconcentration technologies, Hypercon and Aerocon.”
James "Jim" Daly, Halozyme Board Director
“I am pleased to rejoin Halozyme's Board at such an exciting time in the company's evolution. Halozyme has created an impressive portfolio of SC delivery technologies, with ENHANZE the clear gold standard in terms of large volume SC delivery, and Hypercon and Aerocon leading the way to enabling more at home delivery of biologic medicines. I am excited to work with the management team and the Board to continue to transform the patient treatment experience and potentially outcomes.”
Halozyme Announces Appointment of Jim Daly to its Board of Directors PR Newswire
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceutical executive with more than three decades of commercial leadership experience and a proven track record of shaping the profile of innovative therapies resulting in highly successful launches of respiratory, oncology and immunology therapies.
Get started
Create a free account to read the full story.